Oramed Pharmaceuticals Inc. (ORMP) News
Filter ORMP News Items
ORMP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ORMP News From Around the Web
Below are the latest news stories about ORAMED PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORMP as an investment opportunity.
Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year agoInvesting in stocks comes with the risk that the share price will fall. And there's no doubt that Oramed... |
ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT JV with HTIT to help commercialize ORMD–0801 … Oramed Pharmaceuticals (NASDAQ:ORMP) continues to advance its proprietary oral protein delivery platform and is researching the technology potentially to treat diabetes, NASH (nonalcoholic steatohepatitis (NASH), and obesity, as an appetite suppressant, and a COVID vaccine, among other |
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding CompanySorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, "Scilex") of certain securities that Sorrento held in Scilex. |
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed. The Note is the culmination of Scilex's assumption of Sorrento Therapeutics Inc.'s ("Sorrento") approximately $100 million senior secured Debtor In Possession ("DIP") term loan facility with Oramed. Oramed previously annou |
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”). Pursuant to that certain Stock Purchase Agreement entered into on Septem |
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderPALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non |
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. ("HTIT") to establish a joint venture ("JV") based on Oramed's oral drug delivery technology. The proposed JV would focus on the development and worldwide commercialization of innovative products based on Oramed's oral insulin and POD™ (Protein Oral Delivery) pipeline and HTIT's manufacturing capabilities and technologies. The J |
Oramed to Present at the 83rd American Diabetes Association ConferenceOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California. |
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
ORMP: Advancing Development Efforts in ChinaBy M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Licensing deal – potential royalty payments if product is commercialized in China … Earlier this month, Oramed Pharmaceuticals’ (NASDAQ:ORMP) partner in China, Hefei Tianhui Biotechnology Co. (HTIT), completed a Phase 3 oral insulin clinical trial in China and, based on the results, submitted a marketing authorization application to |